4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
The role of ROS/RNS during inflammation-associated and sporadic carcinogenesis (ROSCAN)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,
"A link between inflammation and cancer has been suspected over a long period of time and in recent years genetic evidence supporting such notion could be obtained. Several signaling pathways, such as NF-κB and STAT3, could be identified by our group as well as other groups to play important roles during tumor promotion and progression. Chronic inflammation leads to the formation of reactive oxyge ...
Voir le projet
2
Participants partenaires
TERMINÉ
Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS)
Date du début: 1 avr. 2008, Date de fin: 30 sept. 2013,
"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to ...
Voir le projet
34
Participants partenaires
TERMINÉ
Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease (EVINCI-study)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2012,
The main purpose of the EVINCI-study is to test the impact of combined “anatomo-functional” non invasive cardiac imaging for detection and characterization of Ischemic Heart Disease (IHD). The EVINCI-study is a prospective clinical European multicenter trial performed in a cohort of 700 patients with suspected IHD. Patients with intermediate pre-test probability will undergo clinical and biohumora ...
Voir le projet
22
Participants partenaires
TERMINÉ
Targeting alpha-particle emitting radionuclides to combat cancer (TARCC)
Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,
"This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides. Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues. As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells. This project proposes the development of improved vectors and targeting ...
Voir le projet